Request Demo
Last update 08 Apr 2026
KHN922
Last update 08 Apr 2026
Overview
Basic Info
Drug Type Dual payload Antibody drug conjugate (Dual payload ADC) |
Synonyms KHN-922 |
Target |
Action antagonists |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Sequence Code 193897L
The sequence is quoted from: *****
Sequence Code 9984986H
The sequence is quoted from: *****
Related
1
Clinical Trials associated with KHN922NCT07514975
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid Tumors
100 Clinical Results associated with KHN922
Login to view more data
100 Translational Medicine associated with KHN922
Login to view more data
100 Patents (Medical) associated with KHN922
Login to view more data
100 Deals associated with KHN922
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 01 Apr 2026 | |
| Neoplasms | Preclinical | China | 28 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free